Petrelintide (ZP8396) is a long-acting amylin analogue developed by Zealand Pharma for the treatment of obesity. Designed for once-weekly subcutaneous administration, it represents Zealand's flagship obesity asset.
Mechanism
Petrelintide is an analogue of native amylin engineered for extended duration of action through structural modifications that resist enzymatic degradation. Like Eloralintide, it targets amylin receptors. The amylin class works principally by slowing gastric emptying, suppressing glucagon, and acting on hypothalamic and area postrema circuits to reduce food intake [1].
Phase 2 Outcomes
Phase 2 monotherapy data have shown dose-dependent weight reduction over 16 weeks with a tolerability profile favourable relative to GLP-1 monotherapy, particularly with respect to nausea incidence and severity. Zealand has also disclosed combination data evaluating Petrelintide alongside a GLP-1 agonist [2].
Position in the Amylin Class
- Cagrilintide (Novo Nordisk): dual amylin and calcitonin receptor agonist, furthest along in combination development (CagriSema).
- Eloralintide (Eli Lilly): selective amylin receptor agonist, combination data with Tirzepatide emerging.
- Petrelintide (Zealand): long-acting amylin analogue, Phase 2 monotherapy and combination data.
Research Availability
See the Petrelintide research profile for receptor pharmacology, clinical-register status and citations, plus availability notifications. Petrelintide is not yet available as a research-grade peptide. The closest in-class compound available for amylin pathway research is Cagrilintide, with the Cagrilintide + Semaglutide blend available for combination work.
References
- [1] Hay DL, et al. "Amylin: pharmacology, physiology, and clinical potential." Pharmacol Rev. 2015;67(3):564-600.
- [2] Zealand Pharma Petrelintide Phase 2 disclosures, 2025-2026.